The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of “bet hedging,” according to a new study published by Harvard Medical School researchers in Cell on Dec. 14.
Read the full story at https://hms.harvard.edu/news/combination-rethink
Like Harvard Medical School on Facebook: https://goo.gl/4dwXyZ
Follow on Twitter: https://goo.gl/GbrmQM
Follow on Instagram: https://goo.gl/s1w4up
Follow on LinkedIn: https://goo.gl/04vRgY
Website: https://hms.harvard.edu/